Pulmonary arterial hypertension trials in Czechia

In Czechia 16 Also abroad 305

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Where
Prague
Age
18 years and over
People
85 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-513613-12-00 · EU 2024-513613-12-00
Phase 3Taking people
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Prague
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07234032 · EU 2025-521769-29-00
No phaseTaking people
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Where
Prague
Age
18 years and over
People
850 worldwide
Run by
Abbott Medical Devices
See details and how to joinNCT06526195
No phaseTaking people
Early Detection of CTEPH in Patients After APE
Where
Brno, Havlíčkův Brod, Hradec Králové, Jihlava, Náchod, Olomouc, Ostrava, Pardubice, Rychnov nad Kněžnou, Tábor
Age
18 years and over
People
500
Run by
Institute of Health Information and Statistics of the Czech Republic
See details and how to joinNCT06865326
No phaseTaking people
Controlled Remote Monitoring and Optimization of Oxygen Therapy in Preterm Infants
Where
České Budějovice, Olomouc, Prague
Age
Up to 36 weeks
People
70
Run by
Institute of Health Information and Statistics of the Czech Republic
See details and how to joinNCT07161908
Phase 4Taking people
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Where
Olomouc, Prague
Age
18 years to 75 years
People
110 worldwide
Run by
AOP Orphan Pharmaceuticals AG
See details and how to joinNCT06317805 · EU 2023-504351-26-01
No phaseEnrolling by invitation
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Where
Olomouc, Prague
Age
18 years and over
People
110 worldwide
Run by
AOP Orphan Pharmaceuticals AG
See details and how to joinNCT06445673
Phase 1/2Taking people
Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)
Where
Prague
Age
18 years and over
People
50 worldwide
Run by
35Pharma Inc.
See details and how to join2025-523010-89-00 · EU 2025-523010-89-00
Phase 3Taking people
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Prague
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07179380 · EU 2025-521558-40-00
Phase 2Taking people
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Where
Olomouc, Prague
Age
18 years and over
People
99 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07318597 · EU 2024-514754-79-00
Phase 3Taking people
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Where
Prague
Age
18 years to 75 years
People
330 worldwide
Run by
Gossamer Bio USA, Inc.
See details and how to joinNCT06274801 · EU 2023-506334-75-00
Phase 3Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Where
Prague
Age
18 years and over
People
1,000 worldwide
Run by
United Therapeutics
See details and how to joinNCT03683186 · EU 2023-509305-68-00
Phase 3Taking people
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Where
Prague
Age
18 years to 75 years
People
486 worldwide
Run by
Inhibikase Therapeutics
See details and how to joinNCT07365332 · EU 2024-520218-23-00
Phase 1/2Taking people
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Where
Prague
Age
18 years to 100 years
People
232 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06649110
Phase 3Not yet taking people in Czechia
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
Where
Olomouc, Praha 4
Age
18 years to 75 years
People
300 worldwide
Run by
VIVUS LLC
See details and how to joinNCT07612657 · EU 2025-524596-24-00
No phaseTaking people
Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure
Where
Prague
Age
18 years and over
People
230
Run by
Institute for Clinical and Experimental Medicine
See details and how to joinNCT06331208